Oral Oncology
Volume 46, Issue 4 , Pages e19-e24 , April 2010

VEGF-C contributes to head and neck squamous cell carcinoma growth and motility

  • Emily M. Benke

      Affiliations

    • Philips Institute of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
    • ,
  • Youngmi Ji

      Affiliations

    • Clinical and Experimental Orthopedics Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD 20892, USA
    • ,
  • Vyomesh Patel

      Affiliations

    • Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, Bethesda, MD 20892, USA
    • ,
  • Huixin Wang

      Affiliations

    • Philips Institute of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
    • ,
  • Hiroshi Miyazaki

      Affiliations

    • Philips Institute of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
    • ,
  • W. Andrew Yeudall

      Affiliations

    • Philips Institute of Oral and Craniofacial Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
    • Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA
    • Massey Cancer Center, Virginia Commonwealth University, Richmond, VA 23298, USA
    • Corresponding Author InformationCorresponding author. Address: Philips Institute of Oral and Craniofacial Molecular Biology, VCU School of Dentistry, 521 North 11th Street, P.O. Box 980566, Richmond, VA 23298-0566, USA. Tel.: +1 804 828 6415; fax: +1 804 828 0150.

Received 24 November 2009 ,Revised 11 February 2010 ,Accepted 12 February 2010.

References 

  1. McMahon S, Chen AY. Head and neck cancer. Cancer Metast Rev. 2003;22:21–24
  2. Perez-Ordonez B, Beauchemin M, Jordan RC. Molecular biology of squamous cell carcinoma of the head and neck. J Clin Pathol. 2006;59:445–453
  3. Walsh JE, Lathers DM, Chi AC, Gillespie MB, Day TA, Young MR. Mechanisms of tumor growth and metastasis in head and neck squamous cell carcinoma. Curr Treat Options Oncol. 2007;8:227–238
  4. Miyahara M, Tanuma J, Sugihara K, Semba I. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer. 2007;110:1287–1294
  5. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev. 1997;18:4–25
  6. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. Nat Rev Cancer. 2007;7:79–94
  7. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992;359:845–848
  8. Ferrara N. Vascular endothelial growth factor. Basic science and clinical progress. Endocr Rev. 2004;25:581–611
  9. Kowanetz M, Ferrara N. Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006;12:5018–5022
  10. Bacon K, Baggiolini M, Broxmeyer H, Horuk R, Lindley I, Mantovani A, et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res. 2002;22:1067–1068
  11. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity. 2000;12:121–127
  12. Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992;258:1798–1801
  13. Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol. 2004;14:195–200
  14. Christofakis EP, Miyazaki H, Rubink DS, Yeudall WA. Roles of CXCL8 in squamous cell carcinoma proliferation and migration. Oral Oncol. 2008;44:920–926
  15. Miyazaki H, Patel V, Wang H, Edmunds RK, Gutkind JS, Yeudall WA. Downregulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res. 2006;66:4279–4284
  16. Mayumi M, Jun-ichi T, Kazumasa S, Ichiro S. Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathologic parameters in oral squamous cell carcinoma. Cancer. 2007;110:1287–1294
  17. Warburton G, Nikitakis NG, Roberson P, Marinos NJ, Wu T, Sauk JJ, et al. Histopathological and lymphangiogenic parameters in relation to lymph node metastasis in early stage oral squamous cell carcinoma. J Oral Maxillofac Surg. 2007;65:475–484
  18. Yeudall WA, Crawford RY, Ensley JF, Robbins KC. MTS1/CDK4I is altered in cell lines derived from primary and metastatic oral squamous cell carcinoma. Carcinogenesis. 1994;15:2683–2686
  19. Cardinali M, Pietraszkiewicz H, Ensley JF, Robbins KC. Tyrosine phosphorylation as a marker for aberrantly regulated growth-promoting pathways in cell lines derived from head and neck malignancies. Int J Cancer. 1995;61:98–103
  20. Miyazaki H, Patel V, Wang H, Ensley JF, Gutkind JS, Yeudall WA. Growth factor-sensitive molecular targets identified in primary and metastatic head and neck squamous cell carcinoma using microarray analysis. Oral Oncol. 2006;42:240–256
  21. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transduction. Trends Biochem Sci. 2003;28:488–494
  22. Matsumoto T, Claesson-Welsh L. VEGF receptor signal transduction. Sci STKE. 2001;2001:RE21
  23. Martin D, Galisteo R, Gutkind JS. CXCL8/IL8 stimulates vascular endothelial growth factor (VEGF) expression and the autocrine activation of VEGFR2 in endothelial cells by activating NFkappaB through the CBM (Carma3/Bcl10/Malt1) complex. J Biol Chem. 2009;284:6038–6042
  24. Kowalski LP, Medina JE. Nodal metastases: predictive factors. Otolaryngol Clin North Am. 1998;31:621–637
  25. O-Charoenrat P, Rhys-Evans P, Eccles SA. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer. 2001;92:556–568
  26. Siriwardena BSMS, Kudo Y, Ogawa I, Udagama MNGPK, Tilakaratne WM, Takata T. VEGF-C is associated with lymphatic status and invasion in oral cancer. J Clin Pathol. 2008;61:103–108
  27. Chandrasekar B, Melby PC, Sarau HM, Raveendran M, Perla RP, Marelli-Berg FM, et al. Chemokine–cytokine cross-talk. The ELR+ CXC chemokine LIX (CXCL5) amplifies a proinflammatory cytokine response via a phosphatidylinositol 3-kinase-NF-kappa B pathway. J Biol Chem. 2003;278:4675–4686
  28. Wang D, Sai J, Carter G, Sachpatzidis A, Lolis E, Richmond A. PAK1 kinase is required for CXCL1-induced chemotaxis. Biochemistry. 2002;41:7100–7107
  29. Wang D, Richmond A. Nuclear factor-kappa B activation by the CXC chemokine melanoma growth-stimulatory activity/growth-regulated protein involves the MEKK1/p38 mitogen-activated protein kinase pathway. J Biol Chem. 2001;276:3650–3659
  30. Chandrasekar B, Bysani S, Mummidi S. CXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell–cell adhesion and aortic smooth muscle cell proliferation. J Biol Chem. 2004;279:3188–3196
  31. Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem. 2000;275:6868–6875
  32. Sanchez-Sanchez N, Riol-Blanco L, De La Rosa G, Puig-Kroger A, Garcia-Bordas J, Martin D, et al. Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. Blood. 2004;104:619–625
  33. Wang J, Sun Y, Song W, Nor JE, Wang CY, Taichman RS. Diverse signaling pathways through the SDF-1/CXCR4 chemokine axis in prostate cancer cell lines leads to altered patterns of cytokine secretion and angiogenesis. Cell Signal. 2005;17:1578–1592
  34. Tan W, Martin D, Gutkind JS. The G{alpha}13-rho signaling axis is required for SDF-1-induced migration through CXCR4. J Biol Chem. 2006;281:39542–39549
  35. Wang J, Zhang X, Thomas SM, Grandis JR, Wells A, Chen ZG, et al. Chemokine receptor 7 activates phosphoinositide-3 kinase-mediated invasive and pro survival pathways in head and neck cancer cells independent of EGFR. Oncogene. 2005;24:5897–5904
  36. Luppi F, Longo AM, de Boer WI, Rabe KF, Hiemstra PS. Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer. 2007;56:25–33
  37. Raskopf E, Vogt A, Sauerbruch T, Schmitz V. SiRNA targeting VEGF inhibits hepatocellular carcinoma growth and tumor angiogenesis in vivo. J Hepatol. 2008;49:977–984
  38. Saidi A, Hagedorn M, Allain N, Verpelli C, Sala C, Bello L, et al. Combined targeting of interleukin-6 and vascular endothelial growth factor potently inhibits glioma growth and invasiveness. Int J Cancer. 2009;125:1054–1064

PII: S1368-8375(10)00053-9

doi: 10.1016/j.oraloncology.2010.02.006

Oral Oncology
Volume 46, Issue 4 , Pages e19-e24 , April 2010

Article Tools

* Image Usage & Resolution